Active Ingredient: GALCANEZUMAB
Galcanezumab (a humanized monoclonal antibody targeting CGRP used for migraine prevention) may not cause clinically relevant changes in QTcF interval, blood pressure, or pulse. In a pooled analysis of three randomized placebo-controlled trials across 2886 patients receiving monthly subcutaneous doses of 120 mg or 240 mg for up to 6 months, cardiovascular adverse events were low and similar to placebo (2.6% and 3.3% versus 2.9%). Categorical and mean changes from baseline in Fridericia-corrected QT interval were comparable to placebo.
https://doi.org/10.1111/head.13684